MK-1775
Total Payments
$50,241
Transactions
13
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2017 | $50,241 | 13 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $50,241 | 13 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Randomized, Phase II Study Evaluating MK-1775 in Combination with Paclitaxel and Carboplatin versus Paclitaxel and Carboplatin Alone in Adult Patients with Platinum Sensitive p53 Mutant Ovarian Cancer | Merck Sharp & Dohme Corporation | $50,241 | 0 |
Top Doctors Receiving Payments for MK-1775
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Saint Louis, MO | $50,241 | 13 |
Ad
Manufacturing Companies
- Merck Sharp & Dohme Corporation $50,241
Product Information
- Type Drug
- Total Payments $50,241
- Total Doctors 0
- Transactions 13
About MK-1775
MK-1775 is a drug associated with $50,241 in payments to 0 healthcare providers, recorded across 13 transactions in the CMS Open Payments database. The primary manufacturer is Merck Sharp & Dohme Corporation.
Payment data is available from 2017 to 2017. In 2017, $50,241 was paid across 13 transactions to 0 doctors.
The most common payment nature for MK-1775 is "Unspecified" ($50,241, 100.0% of total).
MK-1775 is associated with 1 research study, including "A Randomized, Phase II Study Evaluating MK-1775 in Combination with Paclitaxel and Carboplatin versus Paclitaxel and Carboplatin Alone in Adult Patients with Platinum Sensitive p53 Mutant Ovarian Cancer" ($50,241).